Bryostatin-1 is under clinical development by Synaptogenix and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase I drugs for Multiple Sclerosis have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Bryostatin-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bryostatin-1 overview
Bryostatin-1 is under development for the treatment of amyotrophic lateral sclerosis (ALS) and multiple sclerosis. It is administered as an intravenous infusion. The drug candidate belongs to family of natural marine cyclic macrolides. It acts by targeting protein kinase C (PKC isozymes).
It was under development for the treatment of Alzheimer's disease, relapsed, refractory acute lymphoblastic leukemia, lymphoma, depression, Parkinson's disease, Rett syndrome, Niemann-Pick type C, Fragile X Syndrome (FXS), stroke and traumatic brain injury.
Synaptogenix overview
Synaptogenix is a clinical-stage biotech company. The company carries out the discovery and development of regenerative therapeutics for neurodegenerative diseases and developmental disorders. The company leverages Bryostatin-1 and its analogues to create targeted, novel treatments. Its major products include synaptogenic treatment approaches for a range of serious and difficult-to-treat diseases. Its products are focused on addressing conditions such as Alzheimer’s disease, Fragile X Syndrome, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, Stroke, and Autism Spectrum Disorders. The company’s applications of products span across the healthcare industry, specifically in the treatment of neurodegenerative diseases and developmental disorders. Synaptogenix is headquartered in New York, New York, the US.
For a complete picture of Bryostatin-1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
